BeStock  
Stocks › Biotechnology › SGMT

Sagimet Biosciences SGMT

US equityMarket cap rank #3594Biotechnology
$8.88 +$0.12 (+1.37%)
Pre-market · Oct 8, 8:20 am ET · After hours $8.88 0.00%
Open$8.65
Prev close$8.76
Day range$8.60 – $8.97
Volume631.6K
Market cap$629.67M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership74.4%-10.94 pts vs. prior quarter
Institutions holding138+0 vs. prior quarter
Insider trades (recent)37 buys / 13 sellsNet buying
Short interest16.51% of floatDays to cover 10.6 · as of 15 Sep 2026
Short-sale volume share28.8%5-day average of daily volume

Short-sale volume as % of daily volume

12%19%27%34%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: +$652.8K (8 inflow days, 12 outflow days).

Net flow by order size, last 20 sessions

+$1.1MSuper−$459.6KBig−$760.6KMid−$526.7KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 26.9% of shares outstanding.

Largest holders

  • BlackRock9.27%
  • Balyasny Asset Management L.P.5.11%
  • Woodline Partners LP4.23%
  • Vanguard Capital Management, LLC4.18%
  • Silverarc Capital Management, LLC4.13%
  • Caligan Partners, LP3.53%
  • BVF Partners L.P.3.53%
  • Affinity Asset Advisors, LLC3.52%

By investor type

  • Hedge Fund34.04%
  • Mutual Fund29.09%
  • VC/PE Fund6.21%
  • Public Company4.43%
  • Individual/Insider0.96%
  • Private Company0.23%
  • Insurance Company0.18%
  • Government Pension Fund0.10%

Reported short interest has risen from 13.36% to 16.51% of float over the last 6 biweekly reports (30 Jun 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
BlackRock Mutual Fund 2026/Q3 +5,775,845 9.3%
Balyasny Asset Management L.P. Hedge Fund 2026/Q3 +3,626,113 5.1%
Silverarc Capital Management, LLC Hedge Fund 2026/Q3 +2,927,698 4.1%
BVF Partners L.P. Hedge Fund 2026/Q3 +2,500,000 3.5%
Caligan Partners, LP Hedge Fund 2026/Q3 +2,500,000 3.5%
Federated Hermes, Inc. Mutual Fund 2026/Q3 +2,085,934 2.9%
Great Point Partners, LLC VC/PE Fund 2026/Q3 +2,029,933 2.9%
Woodline Partners LP Hedge Fund 2026/Q3 +1,999,709 4.2%
State Street Global Advisors Mutual Fund 2026/Q3 +1,866,304 2.8%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +1,705,573 4.2%
Affinity Asset Advisors, LLC Hedge Fund 2026/Q3 +1,629,844 3.5%
Saturn V Capital Management LP Hedge Fund 2026/Q3 +1,479,918 2.1%
Geode Capital Management, LLC Mutual Fund 2026/Q3 +1,134,497 2.0%
CHI Advisors LLC VC/PE Fund 2026/Q3 +926,667 1.8%
abrdn plc Mutual Fund 2026/Q3 +847,700 1.2%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
13 Aug 2026 George Kemble Executive Chairperson Derivative Exercise and Sale -350,987 $10.23 24,474
10 Aug 2026 George Kemble Executive Chairperson Derivative Exercise and Sale -20,206 $9.95 24,474
19 Jul 2026 George Kemble Executive Chairperson Automatic Disposition -18,844 $7.46 24,474
19 Jul 2026 David Happel Chief Executive Officer Open Market Disposition -64,051 $7.76 370,343
19 Jul 2026 Elizabeth Rozek Chief Compliance Officer Open Market Disposition -10,545 $7.76 102,204
11 Jun 2026 Beth Seidenberg Independent Director Other Derivative Acquisition +39,567 $6.48 39,567
11 Jun 2026 Elizabeth Grammer Independent Director Other Derivative Acquisition +39,567 $6.48 39,567
11 Jun 2026 George Kemble Executive Chairperson Other Derivative Acquisition +39,567 $6.48 39,567
11 Jun 2026 Anne Phillips Director Other Derivative Acquisition +39,567 $6.48 39,567
11 Jun 2026 Paul Hoelscher Director Other Derivative Acquisition +39,567 $6.48 39,567
11 Jun 2026 Jennifer Jarrett Director Other Derivative Acquisition +39,567 $6.48 39,567
27 May 2026 David Happel Chief Executive Officer Other Derivative Acquisition +300,000 $7.27 300,000
27 May 2026 Elizabeth Rozek Chief Compliance Officer Other Derivative Acquisition +100,000 $7.27 100,000
27 May 2026 Andreas Grauer Chief Medical Officer Other Derivative Acquisition +35,000 $7.27 35,000
27 May 2026 Thierry Chauche Chief Financial Officer Other Derivative Acquisition +50,000 $7.27 50,000
19 Apr 2026 Andreas Grauer Chief Medical Officer Other Derivative Acquisition +264,759 $6.44 264,759
18 Feb 2026 Eduardo Martins Chief Medical Officer Other Acquisition +44,000 – 114,285
18 Feb 2026 Eduardo Martins Chief Medical Officer Other Derivative Acquisition +88,000 $5.38 88,000
18 Feb 2026 David Happel Chief Executive Officer Other Acquisition +128,000 – 527,455
18 Feb 2026 David Happel Chief Executive Officer Other Derivative Acquisition +256,000 $5.38 256,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 10,262,901 16.5% 10.6
31 Aug 2026 10,112,756 16.3% 9.6
14 Aug 2026 11,746,200 18.9% 6.9
31 Jul 2026 11,595,503 18.8% 16.3
15 Jul 2026 9,743,203 15.8% 9.2
30 Jun 2026 8,252,474 13.4% 3.9

Discussion

No comments yet — be the first to weigh in on SGMT.

Leave a comment

Scroll to Top